Author

S. Ducat

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

C. Piedra-Mora· 2 shared D. H. Barouch· 2 shared A. Chandrashekar· 1 shared A. Colarusse· 1 shared A. Cook· 1 shared A. J. Martinot· 1 shared A. Martinot· 1 shared A. Van Ry· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. Piedra-Mora

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ad26.COV2.S Prevents SARS-CoV-2 Induced Pathways of Inflammation and Thrombosis in Hamsters

M. Aid, S. Vidal, C. Piedra-Mora, S. Ducat, C. Chan, S. Bondoc, A. Colarusse, C. Starke, M. Nekorchuk, K. Busman-Sahay, J. Estes, A. Martinot, D. H. Barouch

This study shows that Ad26.COV2.S vaccine prevents SARS-CoV-2-induced inflammation and thrombosis in hamsters by reducing proinflammatory and prothrombotic pathways and restoring gene expression profiles to uninfected levels.

bioRxiv · Sep 30, 2021 · PreprintMicrobiology

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

X. He, A. Chandrashekar, R. C. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. Rosendahl Huber, L. van der Fits, E. N. Borducchi, , D. H. Barouch

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

bioRxiv · Jan 27, 2021Immunology